TrialNanomedicine (London, England)2025

Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer.

Ching-Wen Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.